NAIROBI, Kenya – Kenya is staring at a looming crisis in its fight against HIV/AIDS, with antiretroviral (ARV) drug stocks expected to last only six more months following the suspension of U.S. funding to the health sector.
This has triggered growing anxiety among patients, some of whom have begun stockpiling medication in anticipation of shortages.
The funding freeze by the United States Agency for International Development (USAID) has had far-reaching consequences, affecting not only drug supplies but also thousands of health workers whose jobs were tied to donor-supported programs.
Counties have admitted they lack the capacity to absorb over 41,000 affected employees, a significant portion of whom were providing critical health services.
These concerns were raised during a multi-sectoral consultative meeting on HIV and syndemic diseases at Lake Naivasha Resort, where stakeholders acknowledged the dire impact of the funding cuts.
Khatra Ali, a board member of the National Syndemic Diseases Control Council (NSDCC) and a representative of the Council of Governors (COG), highlighted the increasing strain on HIV patients.
She noted that rising uncertainty over ARV availability has led to long queues at hospitals as patients rush to secure their medication.
“The supplies we have will last for just six months,” Ali warned. “People want to keep stock because they don’t want to find themselves in a mess.”
She further revealed that the funding freeze has disrupted multiple health programs, including tuberculosis (TB) and malaria initiatives, many of which rely heavily on donor support. Additionally, Kenya risks losing critical health data stored in U.S.-managed systems if access is not secured within 90 days.
Despite these concerns, NSDCC CEO Dr. Ruth Masha sought to reassure the public, stating that Kenya still has adequate ARV supplies and is working with other development partners to maintain stability.
“The Kenyan government provides ARVs, not just the donors. While the U.S. contribution was significant, we are exploring other funding streams and reorganizing ourselves,” Masha said. “Patients should continue taking their medication; we do not anticipate running out of drugs.”
